Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Pharmaceuticals, Life Sciences Show D...
Home  »  Community News  »  Pharmaceuticals, Lif...
Pharmaceuticals, Life Sciences Show Dramatic Jump in Merger Activity
Pharma News

The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsedtransactions from all of 2014.

The first-quarter Pharmaceutical and Life Sciences Deals Insights Quarterly from PwC noted that the deal value amounted to four times the amount in the previous three-month period despite recording only four additional mergers.

During 2014 as a whole, those industries saw 161 transactions totaling $150.1 billion in value.

The analysis also did not account for 49 announced and pending first-quarter deals that would total another $76 billion.

In the pharmaceutical industry alone, 18 transactions totaled $97.4 billion in value. Another 21 deals in that sector worth $62.1 billion were announced in the first quarter, including takeovers ofPharmacyclics by AbbVie and Hospira by Pfizer.

PwC analysts expected merger activity to remain robust throughout 2015 as companies seek stronger pipelines and expanded capabilities.

The report said company divestitures should open more acquisition targets and noted ongoing restructuring in generic pharmaceuticals. The strong dollar is expected to generate additional targets outside the U.S., while industry consolidation and asset swaps should remain prevalent.

The PwC report included disclosed mergers and acquisitions worth at least $15 million and involving U.S.-based companies in biotechnology, medical devices, medical diagnostics, pharmaceuticals or related services.

Leave a reply

You must be logged in to post a comment.